开云app官网登录入口网页版-官方正版

#EGFR敏感#

15篇内容 | 569人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1785065, encodeId=79b71e8506531, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, objectType=article, longId=739082, objectId=0c30e3908258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c30e3908258, replyNumber=0, likeNumber=71, createdTime=2023-02-14, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c30e3908258, moduleTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c30e3908258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785061, encodeId=835b1e850614b, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, objectType=article, longId=293790, objectId=a320293e9099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a320293e9099, replyNumber=0, likeNumber=78, createdTime=2022-02-25, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a320293e9099, moduleTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a320293e9099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785064, encodeId=e9971e85064d8, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, objectType=article, longId=728900, objectId=2d14e28900af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d14e28900af, replyNumber=0, likeNumber=67, createdTime=2022-07-29, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d14e28900af, moduleTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2d14e28900af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785062, encodeId=b5ce1e85062e1, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, objectType=article, longId=295260, objectId=94052952604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94052952604f, replyNumber=0, likeNumber=97, createdTime=2022-12-08, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94052952604f, moduleTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=94052952604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785063, encodeId=998e1e8506393, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295269, objectId=bfe4295269f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4295269f7, replyNumber=0, likeNumber=70, createdTime=2022-05-10, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4295269f7, moduleTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=bfe4295269f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785060, encodeId=33b51e85060f2, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=马学真教授：EGFR敏感突变晚期非小细胞肺癌NSCLC的全程管理要注重“线”的序贯和“面”的联合, objectType=article, longId=198315, objectId=3b9b198315c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b9b198315c9, replyNumber=0, likeNumber=75, createdTime=2021-05-22, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b9b198315c9, moduleTitle=马学真教授：EGFR敏感突变晚期非小细胞肺癌NSCLC的全程管理要注重“线”的序贯和“面”的联合, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3b9b198315c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785059, encodeId=771a1e8505977, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, objectType=article, longId=190912, objectId=52ec19091290, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52ec19091290, replyNumber=0, likeNumber=80, createdTime=2020-10-06, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52ec19091290, moduleTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=52ec19091290)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785057, encodeId=9a741e850572e, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=陈良安教授：EGFR敏感突变晚期NSCLC治疗策略, objectType=article, longId=175124, objectId=eb5f1e51243e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb5f1e51243e, replyNumber=0, likeNumber=66, createdTime=2019-11-04, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb5f1e51243e, moduleTitle=陈良安教授：EGFR敏感突变晚期NSCLC治疗策略, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=eb5f1e51243e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785053, encodeId=69821e85053e7, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=EGFR敏感突变晚期NSCLC靶向治疗研究进展及治疗策略, objectType=article, longId=166827, objectId=1cda16682e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cda16682e88, replyNumber=0, likeNumber=78, createdTime=2019-08-21, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cda16682e88, moduleTitle=EGFR敏感突变晚期NSCLC靶向治疗研究进展及治疗策略, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1cda16682e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785058, encodeId=ac9e1e85058c9, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=EGFR敏感突变晚期NSCLC患者的TKI治疗策略, objectType=article, longId=175265, objectId=8f8b1e5265b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8b1e5265b4, replyNumber=0, likeNumber=70, createdTime=2019-10-22, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8b1e5265b4, moduleTitle=EGFR敏感突变晚期NSCLC患者的TKI治疗策略, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8f8b1e5265b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785052, encodeId=50fa1e850525d, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位, objectType=article, longId=163018, objectId=a01b163018c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a01b163018c7, replyNumber=0, likeNumber=63, createdTime=2019-12-27, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a01b163018c7, moduleTitle=徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a01b163018c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785054, encodeId=560f1e8505403, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=张力教授：EGFR敏感突变晚期NSCLC一线治疗，奥希替尼优势明显, objectType=article, longId=167122, objectId=8e2116e1220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e2116e1220a, replyNumber=0, likeNumber=59, createdTime=2020-01-22, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e2116e1220a, moduleTitle=张力教授：EGFR敏感突变晚期NSCLC一线治疗，奥希替尼优势明显, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8e2116e1220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785055, encodeId=0b461e85055a5, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=吉非替尼联合化疗有望成为EGFR敏感突变晚期NSCLC一线治疗新选择, objectType=article, longId=168215, objectId=efa11682150c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efa11682150c, replyNumber=0, likeNumber=73, createdTime=2020-01-19, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efa11682150c, moduleTitle=吉非替尼联合化疗有望成为EGFR敏感突变晚期NSCLC一线治疗新选择, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=efa11682150c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785056, encodeId=630a1e8505653, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=奥希替尼将成为国内EGFR敏感突变晚期NSCLC一线治疗**, objectType=article, longId=168256, objectId=8f0e1682568c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0e1682568c, replyNumber=0, likeNumber=56, createdTime=2020-04-21, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0e1682568c, moduleTitle=奥希替尼将成为国内EGFR敏感突变晚期NSCLC一线治疗**, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8f0e1682568c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785051, encodeId=91741e85051d9, content=<a href='/topic/show?id=c1936588a8' target=_blank style='color:#2F92EE;'>#EGFR敏感#</a>, objectTitle=CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌, objectType=article, longId=121901, objectId=1fe812190145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fe812190145, replyNumber=0, likeNumber=58, createdTime=2018-02-05, rootId=0, userName=ms6519009802973839, userId=fcba2500108, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fe812190145, moduleTitle=CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1fe812190145)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

EGFR敏感

2020-05-29

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）

2023-02-14

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后

2022-02-25

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较

2022-07-29

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较

2022-12-08

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效

2022-05-10

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

马学真教授：EGFR敏感突变晚期非小细胞肺癌NSCLC的全程管理要注重“线”的序贯和“面”的联合

2021-05-22

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑

2020-10-06

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

陈良安教授：EGFR敏感突变晚期NSCLC治疗策略

2019-11-04

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

EGFR敏感突变晚期NSCLC靶向治疗研究进展及治疗策略

2019-08-21

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

EGFR敏感突变晚期NSCLC患者的TKI治疗策略

2019-10-22

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位

2019-12-27

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

张力教授：EGFR敏感突变晚期NSCLC一线治疗，奥希替尼优势明显

2020-01-22

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

吉非替尼联合化疗有望成为EGFR敏感突变晚期NSCLC一线治疗新选择

2020-01-19

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

奥希替尼将成为国内EGFR敏感突变晚期NSCLC一线治疗**

2020-04-21

ms6519009802973839 (审核中...)

前往app查看评论内容

#EGFR敏感#

CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌

2018-02-05

科室
- - 订阅+
  - 更多科室
工具
服务